Nitric oxide (NO) functions at all levels of the autonomic nervous system to infl uence sympathetic and parasympathetic control of cardiovascular function. It modulates the excitability of peripheral sensory and motor neurons of cardiovascular refl exes and the central neurons that integrate their function. Its effects within this system are diverse and site specifi c and are (at many levels) not well defi ned. However, most evidence suggests that the neuromodulator's infl uence acts to restrain sympathetic outfl ow and facilitate parasympathetic outfl ow. In chronic heart failure, these functional effects of NO are impaired or downregulated and contribute to the state of sympathetic overactivation and parasympathetic deactivation characterized by the disease. The cellular and molecular mechanisms regulating NO production and signaling in the autonomic nervous system in the normal and chronic heart failure state are summarized and discussed in light of their therapeutic implications. This review also emphasizes questions of regulation of NO function in the autonomic nervous system that remain unresolved.
Introduction
Nitric oxide (NO) is well recognized as a modulator of synaptic excitability of many types of neurons. NO signaling exerts signifi cant effects on autonomic control of cardiovascular function and contributes to the dysfunctional state of the sympathetic and parasympathetic nervous system in several cardiovascular diseases, including chronic heart failure (CHF) [1] .
CHF is characterized by chronic elevation in sympathetic outfl ow to the heart and vasculature and an impairment of vagal control of the heart. This change in autonomic "tone" is a major contributor to arrhythmias and cardiac decompensation, which hasten mortality in patients with CHF [1, 2] . Numerous neurohumoral alterations have been documented in the development of heart failure that impact autonomic function [3] . However, these effects are exacerbated by derangements of NO signaling that impact the afferent, central, and efferent neural pathways of sympathetic and parasympathetic function. This review summarizes our knowledge of the role of NO in altered autonomic function in CHF.
Basic Mechanisms of NO Regulation and Signaling in the Autonomic Nervous System
NO is produced by three isoforms of NO synthase (NOS): NOS1 (neural), NOS2 (inducible), and NOS3 (endothelial). All three isoforms have been shown to infl uence autonomic neural function in some way (Table 1) . NOSpositive autonomic neurons primarily express NOS1, but NOS3 and NOS2 immunostaining have been found in neurons and astrocytes in the brainstem [4, 5] . NOS1 and NOS3 are under tight transcriptional control, and their protein levels can be markedly altered in a variety of conditions, including CHF. In autonomic nerves and most vascular beds, NOS1 and NOS3 are downregulated in CHF [6, 7] , but there are exceptions (eg, cardiac tissue) [8] . The cellular signaling pathways and transcription factors responsible for changes in NOS expression in CHF are not well defi ned. In particular, the NOS1 gene, unlike NOS3 and NOS2, is an extremely large and complex locus, giving rise to numerous diverse DNA coding sequences [9] . Some of the known variant mRNA transcripts result in truncated proteins for which function is not well understood [9] .
Post-translational regulation of NOS activity is extensive, making NOS one of the most highly regulated enzymes known and conferring diverse signaling mechanisms by which cells can rapidly control NO production [10]. Of foremost importance, dimerization of NOS protein and activation of enzyme activity requires calcium (Ca 2+ )-activated calmodulin binding. In central neurons, NOS1 is commonly activated by postsynaptic N-methyld-aspartate (NMDA) receptor activation, allowing Ca 2+ infl ux [11] . NOS1 protein possesses an amino acid sequence at the N-terminal region that allows binding to specifi c postsynaptic density or scaffolding proteins, channels; cGMP-cyclic guanosine monophosphate; CHF-congestive heart failure; GABA-γ-aminobutyric acid; KV-voltage-gated K + ; NA-nucleus ambiguus; NMDA-N-methyl-D-aspartic acid; NO-nitric oxide; NOS-nitric oxide synthase; NTS-nucleus tractus solitarii; PDE2-phosphodiesterase 2; PDE3-phosphodiesterase 3; PG-prostaglandin; PKA-protein kinase A; PVN-paraventricular nucleus; RVLMrostral ventrolateral medulla.
